natgillin/translations-raw huggingface dataset:
No treatment related mortalities were noted in juvenile rats dosed at 1,000 mg/kg darunavir (single dose) on day 26 of age or at 500 mg/kg (repeated dose) from day 23 to 50 of age, and the exposures and toxicity profile were comparable to those observed in adult rats.
Nije bila zabilježena smrtnost uslijed liječenja mladih štakora pri dozi od 1000 mg/kg darunavira (jednokratna doza) na 26. dan starosti ili pri dozama od 500 mg/kg (ponovljene doze) od 23. do 50 dana starosti.
Flecainide
Flekainid
If antidepressants are co-administered with boosted darunavir, the recommended approach is a dose titration of the antidepressant based on a clinical assessment of antidepressant response.
Ako se antidepresivi primjenjuju istodobno uz pojačani darunavir, preporučeni pristup je titracija doze antidepresiva temeljeno na kliničkoj procjeni odgovora na antidepresiv.
≥ 1.0 log10 decrease from baseline in plasma viral load a
≥ 1.0 log10 sniženje virusnog opterećenja plazme naspram početnih vrijednosti a
However, dizziness has been reported in some patients during treatment with regimens containing darunavir co-administered with cobicistat or low dose ritonavir and should be borne in mind when considering a patient's ability to drive or operate machinery (see section 4.8).
Međutim, prijavljena je omaglica kod nekih bolesnika tijekom liječenja režimima koji su sadržavali darunavir primijenjen istodobno s kobicistatom ili niskom dozom ritonavira, što se mora imati na umu kada se procjenjuje bolesnikova sposobnost vožnje ili upravljanja strojevima (vidjeti dio 4.8).
If there is evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, hepatomegaly) in patients using darunavir/ritonavir, interruption or discontinuation of treatment should be considered promptly.
Ako postoje dokazi o novoj ili pogoršanju disfunkcije jetre (uključujući klinički značajno povišenje enzima jetre i/ili simptomi poput umora, anoreksije, mučnine, žutice, tamne mokraće, osjetljivosti jetre, hepatomegalije) kod bolesnika koji uzimaju lijek darunavir/ritonavir, mora se odmah razmotriti privremeni ili trajni prekid liječenja.
The maraviroc dose should be 150 mg twice daily when coadministered with darunavir with low dose ritonavir.
Doza maraviroka mora biti 150 mg dva puta na dan kada se primjenjuje istodobno s darunavirom u kombinaciji s niskom dozom ritonavira.
Darunavir Mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4.2):
Tablete Darunavir Mylan od 75 mg, 150 mg, 300 mg i 600 mg mogu se primjenjivati da bi se osigurali prikladni režimi doziranja (vidjeti dio 4.2):
● In all other ART-experienced patients or if HIV-1 genotype testing is not available, the recommended dose regimen described in the Summary of Product Characteristics for darunavir 75 mg, 150 mg, 300 mg and 600 mg tablets.
U svih ostalih bolesnika prethodno liječenih ART-om ili u slučaju nemogućnosti genotipizacije HIV-1, preporučeni režim doziranja je opisan u Sažetku opisa svojstava lijeka za darunavir 75 mg, 150 mg, 300 mg i 600 mg tablete.
Clinical monitoring is recommended when co-administering boosted darunavir with these sedatives/hypnotics and a lower dose of the sedatives/hypnotics should be considered.
Preporučuje se kliničko praćenje kada se istodobno primjenjuje pojačani darunavir s tim sedativima/hipnoticima i u obzir treba uzeti nižu dozu sedativa/hipnotika.
These patients received darunavir 800 mg once daily in combination with cobicistat 150 mg once daily with an investigator selected background regimen consisting of 2 active NRTIs.
Ovi bolesnici su primali darunavir 800 mg jedanput na dan u kombinaciji s kobicistatom od 150 mg jedanput na dan s osnovnim liječenjem koje je ukjučilo 2 aktivna NRTI-ja po izboru ispitivača.
Concomitant use of boosted darunavir and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression.
Istodobna upotreba pojačanog darunavira i kortikosteroida koje metabolizira CYP3A (npr. flutikazon propionat ili ostali inhalacijski ili nazalni kortikosteroidi) može povećati opasnost od razvoja sistemskih učinaka kortikosteroida uključujući Cushingov sindrom i adrenalnu supresiju.
Metabolism and nutrition disorders Common anorexia, diabetes mellitus, hypercholesterolaemia, hypertriglyceridaemia, hyperlipidaemia
Poremećaji metabolizma i prehrane često anoreksija, dijabetes melitus, hiperkolesterolemija, hipertrigliceridemija, hiperlipidemija
ANTIMALARIALS Artemether/Lumefantrine 80/480 mg, 6 doses at 0, 8, 24, 36, 48, and 60 hours artemether AUC ↓ 16% artemether Cmin ↔ artemether Cmax ↓ 18% dihydroartemisinin AUC ↓ 18% dihydroartemisinin Cmin ↔ dihydroartemisinin Cmax ↓ 18% lumefantrine AUC ↑ 175% lumefantrine Cmin ↑ 126% lumefantrine Cmax ↑ 65% darunavir AUC ↔ darunavir Cmin ↓ 13% darunavir Cmax ↔
Lumefantrin 80/480 mg, 6 doza u 0., 8., 24., 36., 48. i 60. satu artemeter AUC ↓ 16% artemeter Cmin ↔ artemeter Cmax ↓ 18% dihidroartemisinin AUC ↓ 18% dihidroartemisinin Cmin ↔ dihidroartemisinin Cmax ↓ 18% lumefantrin AUC ↑ 175% lumefantrin Cmin ↑ 126% lumefantrin Cmax ↑ 65% darunavir AUC ↔ darunavir Cmin ↓ 13% darunavir Cmax ↔
When administration of atorvastatin and darunavir coadministered with low dose ritonavir is desired, it is recommended to start with an atorvastatin dose of 10 mg once daily.
Kada se želi primijeniti atorvastatin i darunavir primijenjen istodobno s niskom dozom ritonavira, preporučuje se početi s dozom atorvastatina od 10 mg jedanput na dan.
The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Periodička izvješća o neškodljivosti lijeka (PSUR-evi) Zahtjevi za podnošenje PSUR-eva za ovaj lijek definirani su u referentnom popisu datuma EU (EURD popis) predviđenom člankom 107.c stavkom 7.
Proportion (%) of patients with response (HIV-1 RNA < 50 copies/ml at week 24) to darunavir coadministered with ritonavir (600/100 mg twice daily) by baseline genotype a, and baseline darunavir FC and by use of enfuvirtide (ENF): As treated analysis of the POWER and DUET trials.
Udio (%) bolesnika s odgovorom (HIV-1 RNK< 50 kopija/ml u 24. tjednu) na darunavir primijenjen istodobno s ritonavirom (600/100 mg dva puta na dan) po početnom genotipu a i početnoj PV darunavira te prema primjeni enfuvirtida (ENF): analiza POWER i DUET ispitivanja prema realiziranom liječenju.
Medicinal products that affect darunavir exposure (cobicistat as pharmacoenhancer)
Lijekovi koji utječu na izloženost darunaviru (uz kobicistat kao farmakokinetički pojačivač)
(-4.6; 9.2)d d d
(-5,2; 7,9)d d
The metabolism of alfentanil is mediated via CYP3A, and may as such be inhibited by darunavir co-administered with low dose ritonavir.
Metabolizam alfentanila posredovan je putem CYP3A, i kao takav može biti inhibiran darunavirom istodobno primijenjenom s niskom dozom ritonavira.
Increased AST/ALT monitoring should be considered in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre-treatment elevations of transaminases, especially during the first several months of darunavir used in combination with cobicistat or low dose ritonavir treatment.
Mora se razmotriti pojačano praćenje AST/ALT kod bolesnika s podležećim kroničnim hepatitisom, cirozom ili kod bolesnika koji su prije liječenja imali povišenja transaminaza, posebno tijekom prvih nekoliko mjeseci liječenja darunavirom koji se uzima u kombinaciji s kobicistatom ili niskom dozom ritonavira.
Darunavir may therefore have different recommendations for concomitant medications depending on whether the compound is boosted with ritonavir or cobicistat.
Stoga su moguće različite preporuke za uzimanje darunavira istodobno primijenjenim lijekovima, ovisno o tome je li pojačan s ritonavirom ili s kobicistatom.
Dose for children of 3 years of age and above, weighing at least 15 kilograms who have not taken antiretroviral medicines before (your child's doctor will determine this) The doctor will work out the right once daily dose based on the weight of the child (see table below).
Doza za djecu u dobi od 3 godine i više, težine najmanje 15 kilograma koja prethodno nisu uzimala antiretrovirusne lijekove (to će odrediti liječnik Vašeg djeteta) Liječnik će odrediti pravu dozu koja se uzima jedanput na dan na temelju težine djeteta (vidjeti tablicu ispod).
Darunavir should not be used in paediatric patients below 3 years of age or less than 15 kg body weight (see sections 4.4 and 5.3).
Darunavir se ne smije primjenjivati u pedijatrijskih bolesnika s manje od 3 godine ili s manje od 15 kg tjelesne težine (vidjeti dijelove 4.4 i 5.3).
Darunavir Mylan with food and drink See section 3 ‘How to take Darunavir Mylan'.
Darunavir Mylan s hranom i pićem Vidjeti dio 3 „Kako uzimati lijek Darunavir Mylan“.
#darunavir AUC ↓ 26% darunavir Cmin ↓ 42% #darunavir Cmax ↓ 17% saquinavir AUC ↓ 6% saquinavir Cmin ↓ 18% saquinavir Cmax ↓ 6%
#darunavir AUC ↓ 26% darunavir Cmin ↓ 42% #darunavir Cmax ↓ 17% sakvinavir AUC ↓ 6% sakvinavir Cmin ↓ 18% sakvinavir Cmax ↓ 6%
There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthrosis in patients with haemophilia type A and B treated with PIs.
Prijavljeno je pojačano krvarenje, uključujući spontane kožne hematome i hemartrozu kod bolesnika s hemofilijom tipa
Darunavir with cobicistat or ritonavir has not been tested with all PIs (protease inhibitors) and must not be used with other HIV PIs.
Darunavir s kobicistatom ili ritonavirom nije bio ispitan sa svim IP (inhibitori proteaze) i ne smije se uzimati s drugim IP HIV-a.
Population pharmacokinetic analysis in HIV infected patients showed that darunavir pharmacokinetics are not considerably different in the age range (18 to 75 years) evaluated in HIV infected patients (n=12, age ≥ 65) (see section 4.4).
Analiza populacijskih farmakokinetičkih podataka kod HIV-om inficiranih bolesnika (n=12, dob  65) pokazala je da farmakokinetika darunavira nije bitno različita u rasponu dobi (18 do 75 godina) (vidjeti dio 4.4).
Clinical monitoring is recommended when co-administering boosted darunavir with β-blockers.
Preporučeno je kliničko praćenje kada se darunavir primjenjuje istodobno s β-blokatorima.
Darunavir 400 mg or 800 mg must always be given orally with cobicistat or low dose ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products (see section 5.2).
Darunavir 400 mb i 800 mg se uvijek mora primjenjivati peroralno s kobicistatom ili niskom dozom ritonavira kao farmakokinetičkim pojačivačem, te u kombinaciji s drugim antiretrovirusnim lijekovima. (vidjeti dio section 5.2).
If antidepressants are coadministered with darunavir with low dose ritonavir, the recommended approach is a dose titration of the antidepressant based on a clinical assessment of antidepressant response.
Ako se antidepresivi primjenjuju istodobno uz darunavir s niskom dozom ritonavira, preporučeni pristup je titracija doze antidepresiva temeljeno na kliničkoj procjeni odgovora na antidepresiv.
Ethinylestradiol Norethindrone 35 μg/1 mg once daily drospirenone AUC ↑ 58% drospirenone Cmin ND€
Etinilestradiol Noretindron 35 g/1 mg jedanput na dan drospirenon AUC ↑ 58%€ drospirenon Cmin NO€
Even if you feel better, do not stop taking Darunavir Mylan and ritonavir without talking to your doctor.
Čak i ako se osjećate bolje, ne prekidajte uzimati lijek Darunavir Mylan i ritonavir bez da se posavjetujete sa svojim liječnikom.
Viruses isolated from patients on darunavir/ritonavir 600/100 mg twice daily experiencing virologic failure by rebound that were susceptible to tipranavir at baseline remained susceptible to tipranavir after treatment in the vast majority of cases.
Izolirani virusi u bolesnika na darunaviru/ritonaviru od 600/100 mg dva puta na dan u kojih je došlo virološkog neuspjeha zbog ponovnog porasta virusa u krvi, bili su osjetljivi na tipranavir na početku liječenja u velikoj većini su slučajeva ostali osjetljivi na tipranavir i nakon liječenja.
- if you are allergic to darunavir or any of the other ingredients of this medicine (listed in section 6) or to ritonavir.
- ako ste alergični na darunavir ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.) ili na ritonavir. - ako imate teške jetrene tegobe.
ODIN is a Phase III, randomised, open-label trial comparing darunavir/ritonavir 800/100 mg once daily versus darunavir/ritonavir 600/100 mg twice daily in ART-experienced HIV-1 infected patients with screening genotype resistance testing showing no darunavir RAMs (i.e. V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V) and a screening HIV-1 RNA > 1,000 copies/ml.
ODIN je randomizirano, otvoreno ispitivanje faze III u kojem se darunavir/ritonavir od 800/100 mg jedanput na dan naspram darunavira/ritonavira od 600/100 mg dva puta na dan u bolesnika prethodno liječenih ART-om inficirani virusom HIV-1, a na probiru pri uključivanju u ispitivanje testiranje genotipa u tih bolesnika nije pokazalo mutacije povezane s rezistencijom na darunavir (tj. V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V), dok je probir HIV-1 RNK u plazmi bio > 1000 kopija/ml.
100 milligram a ritonavir oral solution: 80 milligram per milliliter
100 miligrama a oralna otopina ritonavira: 80 miligrama po mililitru
The concomitant use with darunavir and low dose ritonavir may require to lower the dose of alfentanil and requires monitoring for risks of prolonged or delayed respiratory depression.
Istodobna primjena s darunavirom i niskom dozom ritonavira može zahtijevati snižavanje doze alfentanila i zahtijeva praćenje rizika za produljenu ili odgođenu respiratornu depresiju.
The pharmacokinetic enhancing effect of cobicistat on darunavir was evaluated in a Phase I study in healthy subjects that were administered darunavir 800 mg with either cobicistat at 150 mg or ritonavir at 100 mg once daily.
Učinak farmakokinetičkog pojačivača kobicistata na darunavir bio je procijenjen u ispitivanju faze I u zdravih doborovljaca kojima je darunavir od 800 mg bio primijenjen bilo s kobicistatom od 150 mg ili ritonavirom od 100 mg jedanput na dan.
≥ 30 kg to < 40 kg
 30 kg do < 40 kg
Dose for children of 3 years of age and above, weighing at least 15 kilograms who have taken antiretroviral medicines before (your child's doctor will determine this) The doctor will work out the right dose based on the weight of the child (see table below).
Doza za djecu u dobi od 3 godine starosti i više, težine najmanje 15 kilograma koja su prethodno uzimala antiretrovirusne lijekove (to će odrediti liječnik Vašeg djeteta) Liječnik će odrediti pravu dozu na osnovi tjelesne težine djeteta (vidjeti tablicu ispod).
During the second trimester of pregnancy, cobicistat Cmax, AUC24h, and Cmin were 50%, 63%, and 83% lower, respectively, as compared with postpartum.
Tijekom drugog tromjesečja trudnoće, Cmax, AUC24h, i Cmin kobicistata bile su 50%, 63% odnosno 83% niže, u usporedbi s postpartalnim razdobljem.
In-use shelf life after first opening HDPE bottle: 100 days.
Rok valjanosti nakon prvog otvaranja boce od polietilena visoke gustoće (HDPE): 100 dana.
If parenteral midazolam is coadministered with darunavir with low dose ritonavir, it should be done in an intensive care unit (ICU) or similar setting, which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation.
Ako se parenteralni midazolam primjenjuje istodobno s darunavirom s niskom dozom ritonavira, primjena bi morala biti u jedinici intenzivnog liječenja ili sličnom odjelu gdje je osigurano pomno kliničko praćenje, te primjereno medicinsko zbrinjavanje u slučaju respiratorne depresije i/ili produljene sedacije.
If there is evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, hepatomegaly) in patients using darunavir used in combination with cobicistat or low dose ritonavir, interruption or discontinuation of treatment should be considered promptly.
Ako postoje dokazi o novoj ili pogoršanju disfunkcije jetre (uključujući klinički značajno povišenje enzima jetre i/ili simptomi poput umora, anoreksije, mučnine, žutice, tamne mokraće, osjetljivosti jetre, hepatomegalije) kod bolesnika koji uzimaju darunavir koji se uzima u kombinaciji s kobicistatom ili niskom dozom ritonavira, mora se odmah razmotriti privremeni ili trajni prekid liječenja.
The pharmacokinetic properties of darunavir, co-administered with cobicistat or ritonavir, have been evaluated in healthy adult volunteers and in HIV-1 infected patients.
Farmakokinetička svojstva darunavira primijenjenog istodobno s kobicistatom ili ritonavirom, ispitivana su kod zdravih odraslih dobrovoljaca i kod bolesnika inficiranih s HIV-1.
darunavir amprenavir atazanavir indinavir lopinavir saquinavir tipranavir a TLOVR non-VF censored algorithm based on HIV-1 RNA < 50 copies/ml, except for TITAN (HIV-1 RNA < 400
TLOVR ne-VF cenzoriran algoritam na temelju HIV-1 RNK < 50 kopija/ml, osim za ispitivanje TITAN (HIV-1 RNK < 400 kopija/ml)
The maraviroc dose should be 150 mg twice daily when co-administered with boosted darunavir.
Doza maraviroka mora biti 150 mg dva puta na dan kada se primjenjuje istodobno s pojačanim darunavirom.
ART-naïve paediatric patients from the age of 12 years to < 18 years, and weighing at least 40 kg DIONE is an open-label, Phase II trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of darunavir with low dose ritonavir in 12 ART-naïve HIV-1 infected paediatric patients aged 12 to less than 18 years and weighing at least 40 kg.
Pedijatrijski bolesnici koji nisu prethodno liječeni ART-om u dobi od 12 godina do < 18 godina i težine najmanje 40 kg DIONE je otvoreno ispitivanje faze II koje je procijenilo farmakokinetiku, sigurnost, podnošljivost i djelotvornost darunavira s niskom dozom ritonavira u 12 pedijatrijskih bolesnika koji nisu prethodno liječeni ART-om, u dobi od 12 godina do < 18 godina i težine najmanje 40 kg.
Boceprevir 800 mg three times daily boceprevir AUC ↓ 32% boceprevir Cmin ↓ 35% boceprevir Cmax ↓ 25% darunavir AUC ↓ 44% darunavir Cmin ↓ 59% darunavir Cmax ↓ 36%
Boceprevir 800 mg tri puta na dan boceprevir AUC ↓ 32% boceprevir Cmin ↓ 35% boceprevir Cmax ↓ 25% darunavir AUC ↓ 44% darunavir Cmin ↓ 59% darunavir Cmax ↓ 36%
Darunavir boosted with cobicistat is more sensitive to CYP3A induction than ritonavir-boosted darunavir: co-administration of darunavir/cobicistat with medicinal products that are strong inducers of CYP3A (e.g. St John's wort, rifampicin, carbamazepine, phenobarbital, and phenytoin) is contraindicated (see section 4.3).
Darunavir pojačan s kobicistatom je osjetljiviji na CYP3A indukciju u odnosu na darunavir pojačan ritonavirom : kontraindicirana je istodobna primjena darunavira/kobicistata s lijekovima snažnim induktorima CYP3A (npr. gospina trava, rifampicin, karbamazepin, fenobarbital i fenitoin) (vidjeti dio 4.3).
Co-administration with boosted darunavir may cause a large increase in the concentration of these medicines.
Istodobna primjena s pojačanim darunavirom može izazvati velik porast koncentracije tih lijekova.
Darunavir Mylan 75 mg, 150 mg, 300 mg and 600 mg film-coated tablets contain less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free'.
Darunavir Mylan 75 mg, 150 mg, 300 mg i 600 mg filmom obložene tablete sadrže manje od 1 mmol natrija (23 mg) po dozi, tj. zanemarive količine natrija.
If parenteral midazolam is coadministered with boosted darunavir it may cause a large increase in the concentration of this benzodiazepine.
Ako se parenteralni midazolam istodobno primjenjuje s pojačanim darunavirom, to može izazvati velik porast koncentracija ovog benzodiazepina.
The pharmacokinetic properties of darunavir, co-administered with ritonavir, have been evaluated in healthy adult volunteers and in HIV-1 infected patients.
Farmakokinetička svojstva darunavira primijenjenog istodobno s ritonavirom, ispitivana su kod zdravih odraslih dobrovoljaca i kod bolesnika inficiranih s HIV-1.
If concomitant use of boosted darunavir with sildenafil, vardenafil or tadalafil is indicated, sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg in 72 hours or tadalafil at a single dose not exceeding 10 mg in 72 hours is recommended.
Ako je istodobna primjena pojačanog darunavira indicirana sa sildenafilom, vardenafilom ili tadalafilom, tada su preporučene sljedeće doze: jednokratna doza sildenafila ne prelazi 25 mg u 48 sati, jednokratna doza vardenafila ne prelazi 2,5 mg u 72 sata ili jednokratna doza tadalafila ne prelazi 10 mg u 72 sata.
Although the effect on CYP2C8 has only been studied in vitro, co-administration of darunavir and ritonavir and medicinal products primarily metabolised by CYP2C8 (such as paclitaxel, rosiglitazone, repaglinide) may result in decreased systemic exposure to such medicinal products, which could decrease or shorten their therapeutic effect.
Iako je učinak na CYP2C8 bio ispitivan samo in vitro, istodobna primjena darunavira i ritonavira i drugih lijekova koji se primarno metaboliziraju putem CYP2C8 (poput paklitaksela, roziglitazona, repaglinida) može rezultirati smanjenom sistemskom izloženosti tim lijekovima, što može smanjiti ili skratiti njihov terapijski učinak.
If concomitant use of darunavir co-administered with low dose ritonavir with sildenafil, vardenafil or tadalafil is indicated, sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg in 72 hours or tadalafil at a single dose not exceeding 10 mg in 72 hours is recommended.
Ako je istodobna primjena darunavira primijenjenog istodobno s niskom dozom ritonavira indicirana sa sildenafilom, vardenafilom ili tadalafilom, tada su preporučene sljedeće doze: jednokratna doza sildenafila ne prelazi 25 mg u 48 sati, jednokratna doza vardenafila ne prelazi 2,5 mg u 72 sata ili jednokratna doza tadalafila ne prelazi 10 mg u 72 sata.
Darunavir Mylan with food and drink See section 3 ‘How to take Darunavir Mylan.
Darunavir Mylan s hranom i pićem Vidjeti dio 3 “Kako uzimati lijek Darunavir Mylan“.
Rare myocardial infarction, angina pectoris, prolonged electrocardiogram QT, tachycardia acute myocardial infarction, sinus bradycardia, palpitations
Srčani poremećaji manje često rijetko infarkt miokarda, angina pektoris, produljeni QT interval na elektrokardiogramu, tahikardija akutni infarkt miokarda, sinusna bradikardija, palpitacije
Darunavir Mylan 75 mg film-coated tablets Darunavir Mylan 150 mg film-coated tablets Darunavir Mylan 300 mg film-coated tablets Darunavir Mylan 600 mg film-coated tablets
Darunavir Mylan 75 mg filmom obložene tablete Darunavir Mylan 150 mg filmom obložene tablete Darunavir Mylan 300 mg filmom obložene tablete Darunavir Mylan 600 mg filmom obložene tablete
During the third trimester of pregnancy, cobicistat Cmax, AUC24h, and Cmin, were 27%, 49%, and 83% lower, respectively, as compared with postpartum.
Tijekom trećeg tromjesečja trudnoće Cmax, AUC24h, i Cmin kobicistata bile su 27%, 49% odnosno 83% niže, u usporedbi s postpartalnim razdobljem.
Silica, colloidal anhydrous Cellulose microcrystalline Crospovidone Sodium starch glycolate Hypromellose Magnesium stearate
Jezgra tablete silicijev dioksid, koloidni bezvodni mikrokristalična celuloza krospovidon natrijev škroboglikolat hipromeloza magnezijev stearat
rifabutin Cmax darunavir AUC ↑ 53% darunavir Cmin ↑ 68%
rifabutin Cmax darunavir AUC ↑ 53% darunavir Cmin ↑ 68% darunavir Cmax ↑ 39%
Darunavir co-administered with low dose ritonavir and etravirine 200 mg twice daily can be used without dose adjustments.
Darunavir istodobno primijenjen s niskom dozom ritonavira i etravirinom 200 mg dva puta na dan može se primijeniti bez prilagodbe doze.